Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;19(2):2253598.
doi: 10.1080/21645515.2023.2253598.

The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop

Heidi Hempel  1 , Nicholas Mantis  2 , Christopher D Heaney  3 , Ligia A Pinto  1
Affiliations

The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop

Heidi Hempel et al. Hum Vaccin Immunother. .

Abstract

SARS-CoV-2 persists in certain populations, even with vaccination and boosters. Emerging evidence suggests that reductions in virus transmission and infection will likely require involvement of the mucosal immune system, especially secretory antibodies in the upper respiratory tract. The Clinical and Translational Serology Task Force (CTTF) within The National Cancer Institute (NCI)'s Serological Sciences Network for COVID-19 (SeroNet) hosted a workshop to review the status of development and standardization of mucosal sample collection methods and assays, identify challenges, and develop action plans to bridge gaps. Speakers presented data underscoring a role for secretory IgA in protection, mucosal markers as correlates of protection, methods for tracking and assessing mucosal antibodies, and lessons learned from other infectious agents. Perspectives from regulators and industry were put forward to guide mucosal vaccine development. Methodological considerations for optimizing collection protocols and assays and harmonizing data were highlighted. Rigorous studies, standardized protocols, controls, standards, and assay validation were identified as necessary to gain momentum in expanding SARS-CoV-2 vaccines to the mucosa.

Keywords: Mucosal immunology; secretory antibodies; serology; standardization; vaccines.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. Kim C, Kim JD, Seo SU.. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J Microbiol. 2022;60(3):335–5. doi: 10.1007/s12275-022-1608-z. - DOI - PMC - PubMed
    1. Wambani J, Okoth P. Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. Egypt J Intern Med. 2022;34(1):34. doi: 10.1186/s43162-022-00121-z. - DOI - PMC - PubMed
    1. Lopez S. Clinical and translational serology highlights: SeroNews. 2021. https://frederick.cancer.gov/initiatives/serological-sciences-network/se....
    1. Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, Hober S, Gordon M, Blom K, Klingström J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 Omicron infection. N Engl J Med. 2022;387(14):1333–6. doi: 10.1056/NEJMc2209651. - DOI - PMC - PubMed
    1. Marking U, Bladh O, Havervall S, Svensson J, Greilert-Norin N, Aguilera K, Kihlgren M, Salomonsson A-C, Månsson M, Gallini R, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect Dis. 2023;23(2):150–2. doi: 10.1016/s1473-3099(22)00834-9. - DOI - PMC - PubMed

Publication types